Research Paper Volume 16, Issue 21 pp 13323—13339
A differentially-methylated-region signature predicts the recurrence risk for patients with early stage lung adenocarcinoma
Figure 4. Performance of the DMR signature in the model validation cohort. (A) Heat map of the methylation value of the 15 DMRs in low-risk (n = 27) and high-risk (n = 58) groups. (B) KM curves for DFS in the model validation cohort. (C) Time-dependent ROC curves in the model validation cohort. (D) Comparison of the risk score in the different clinical subgroups including age, sex, smoking history, and TNM stage.